Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Bioventus (BVS) Non Operating Income (2020 - 2026)

Bioventus filings provide 6 years of Non Operating Income readings, the most recent being -$5.3 million for Q4 2025.

  • On a quarterly basis, Non Operating Income rose 31.11% to -$5.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$6.8 million, a 81.8% increase, with the full-year FY2025 number at -$28.3 million, up 23.91% from a year prior.
  • Non Operating Income hit -$5.3 million in Q4 2025 for Bioventus, down from -$79000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $2.5 million in Q2 2021 to a low of -$40.0 million in Q4 2023.
  • Median Non Operating Income over the past 5 years was -$2.1 million (2021), compared with a mean of -$5.6 million.
  • Biggest five-year swings in Non Operating Income: surged 2860.24% in 2021 and later tumbled 1737.75% in 2023.
  • Bioventus' Non Operating Income stood at $1.4 million in 2021, then tumbled by 792.21% to -$9.4 million in 2022, then plummeted by 324.55% to -$40.0 million in 2023, then skyrocketed by 80.59% to -$7.8 million in 2024, then soared by 31.11% to -$5.3 million in 2025.
  • The last three reported values for Non Operating Income were -$5.3 million (Q4 2025), -$79000.0 (Q3 2025), and -$561000.0 (Q2 2025) per Business Quant data.